A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma
A Phase 1b Multicenter, Randomized, Single-Masked, Sham-Controlled Study of the Safety and Tolerability of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma
Sponsor: ONL Therapeutics
A PHASE1 clinical study on Open Angle Glaucoma, this trial is completed. The trial is conducted by ONL Therapeutics and has accumulated 6 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Aug 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2022 — Aug 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Jan 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ONL Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .